Hypertension and prohypertensive antineoplastic therapies in cancer patients

van Dorst, D. C.H., Dobbin, S. J.H. , Neves, K. B. , Herrmann, J., Herrmann, S. M., Versmissen, J., Mathijssen, R. H.J., Danser, A.H. J. and Lang, N. N. (2021) Hypertension and prohypertensive antineoplastic therapies in cancer patients. Circulation Research, 128(7), pp. 1040-1061. (doi: 10.1161/CIRCRESAHA.121.318051) (PMID:33793337) (PMCID:PMC8011349)

[img] Text
234068.pdf - Published Version
Available under License Creative Commons Attribution.



The development of a wide range of novel antineoplastic therapies has improved the prognosis for patients with a wide range of malignancies, which has increased the number of cancer survivors substantially. Despite the oncological benefit, cancer survivors are exposed to short- and long-term adverse cardiovascular toxicities associated with anticancer therapies. Systemic hypertension, the most common comorbidity among cancer patients, is a major contributor to the increased risk for developing these adverse cardiovascular events. Cancer and hypertension have common risk factors, have overlapping pathophysiological mechanisms and hypertension may also be a risk factor for some tumor types. Many cancer therapies have prohypertensive effects. Although some of the mechanisms by which these antineoplastic agents lead to hypertension have been characterized, further preclinical and clinical studies are required to investigate the exact pathophysiology and the optimal management of hypertension associated with anticancer therapy. In this way, monitoring and management of hypertension before, during, and after cancer treatment can be improved to minimize cardiovascular risks. This is vital to optimize cardiovascular health in patients with cancer and survivors, and to ensure that advances in terms of cancer survivorship do not come at the expense of increased cardiovascular toxicities.

Item Type:Articles
Additional Information:SD, KBN and NNL are supported by a British Heart Foundation (BHF) Centre of Research Excellence grant (RE/18/6/34217) and a BHF Project Grant (PG/19/64/34434). SMH is supported by National Institutes of Health K08 DK118120 from the NIDDK.
Glasgow Author(s) Enlighten ID:Neves, Dr Karla and Dobbin, Dr Stephen and Lang, Professor Ninian
Authors: van Dorst, D. C.H., Dobbin, S. J.H., Neves, K. B., Herrmann, J., Herrmann, S. M., Versmissen, J., Mathijssen, R. H.J., Danser, A.H. J., and Lang, N. N.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:Circulation Research
Publisher:American Heart Association
ISSN (Online):0009-7330
Published Online:01 April 2021
Copyright Holders:Copyright © 2021 The Authors
First Published:First published in Circulation Research 128(7):1040-1061
Publisher Policy:Reproduced under a Creative Commons licence

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
303944BHF Centre of ExcellenceRhian TouyzBritish Heart Foundation (BHF)RE/18/6/34217CAMS - Cardiovascular Science